Genetic Differences in Heart Muscle Disease Linked to Atrial Fibrillation
Looks at gene variants in people with atrial fibrillation and heart muscle disease.
Plain-language title generated from the registry record
Registry title: AIC Genotyping Study
Key facts
- Where
- London, United KingdomSee the site
Where in United Kingdom
- St Bartholomew's Hospital, Barts Health NHS TrustLondon, United KingdomTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Barts & The London NHS Trust
- Trial code
- NCT07574697
- Record updated
- 8 May 2026
- Original description
To quantify genetic variants in a focused DCM gene panel among AF-induced cardiomyopathy (AIC) and positive/negative controlsRead full original descriptionShow less
Genetic Susceptibility to AF-Induced Cardiomyopathy
To quantify genetic variants in a focused DCM gene panel among AF-induced cardiomyopathy (AIC) and positive/negative controls
INCLUSION:; AIC (Cases):; Age ≥18; Persistent AF before index catheter ablation or cardioversion; LVEF ≤40% during rate-controlled (resting HR <100bpm, mean HR on 24-hour Holter <100bpm) AF prior to index catheter ablation or cardioversion; LVEF normalisation (LVEF ≥55%) in SR, post-catheter ablation or cardioversion (≥3 months post-catheter ablation or cardioversion), no AF (>30 seconds of continuous AF) detected outside blanking period (8 weeks post-catheter ablation), and with no new introduction of any new or increased dose of heart failure guideline-directed medical therapy (GDMT) (renin-angiotensin-aldosterone system inhibitors (RAASi), Sodium Glucose Co-transporter 2 (SLGT2) inhibitors, increased dose of beta-blocker (BB), mineralocorticoid receptor antagonist (MRA)); AF-pEF (Negative controls):; Age ≥18; Persistent AF before index catheter ablation or cardioversion; LVEF ≥55% during rate-controlled (resting HR <100bpm) AF. AIC-genotyping study, v1.7, 27.01.26 Page 13 of 28; AF/HF non-responders (Positive controls); Age ≥18; Persistent AF before index catheter ablation or cardioversion; LVEF ≤40% during rate-controlled (resting HR <100bpm) AF before index catheter ablation or cardioversion; Persistent LVSD (LVEF ≤40%) in SR, post-catheter ablation or cardioversion (≥3 months post-catheter ablation or cardioversion), no AF (>30 seconds of continuous AF) detected outside blanking period (8 weeks post-catheter ablation) and with no change in heart failure GDMT (RAASi, SGLT2 inhibitors, increased dose of BB, MRA); EXCLUSION:; AIC (Cases); No alternative cause for LVSD (ischemic cardiomyopathy/non-ischaemic cardiomyopathy before AF diagnosis, primary valve disease, inherited cardiomyopathy; Any pregnancy during AF or in the 12 months preceding LVSD onset; Alcohol intake >21 units/week; Any history of cardiotoxic chemotherapy; AF-pEF (Negative controls); No known cause for LVSD (ischemic cardiomyopathy/non-ischaemic cardiomyopathy before AF diagnosis, primary valve disease, inherited cardiomyopathy); Any pregnancy during AF or in the 12 months preceding LVSD onset; Alcohol intake >21 units/week; Any history of cardiotoxic chemotherapy; AF/HF non-responders (Positive controls); No alternative cause for LVSD (ischemic cardiomyopathy/non-ischaemic cardiomyopathy before AF diagnosis, primary valve disease, inherited cardiomyopathy); Any pregnancy during AF or in the 12 months preceding LVSD onset; Alcohol intake >21 units/week; Any history of cardiotoxic chemotherapy.